Market research
IVX.AU Invion Limited
AU AUD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 4M
- P/E ratio
- Not available
- Analyst target
- 0.11
- Dividend yield
- Not available
- Beta
- 0.43
Profile
Company facts
- Exchange
- AU
- Currency
- AUD
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- AU000000IVX4
- Market cap
- 4M
- P/E ratio
- Not available
- Analyst target
- 0.11
- Dividend yield
- Not available
- Beta
- 0.43
About
About Invion Limited
Invion Limited, a clinical-stage life sciences company, researches and develops Photosoft technology for the treatment of cancers, atherosclerosis, and infectious diseases in Australia. The company develops IVX-PDT, a photosensitising agent to treat a range of cancers, such as skin, prostate, ano-genital, glioblastoma multiforme, lung, and ovarian cancers; and human papilloma virus. It is also involved in the development of INV043, which is in Phase II clinical trial for the treatment of patients with prostate cancer; and in Phase I/II clinical trial to treat non-melanoma skin cancer, as well as for the treatment of oesophageal cancer. The company has collaborations with Hudson Institute of Medical Research, Peter MacCallum Cancer Centre, Dr. I&B Co., Ltd., and Hanlim Pharm Co., Ltd. Invion Limited was incorporated in 2000 and is headquartered in Melbourne, Australia.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the IVX.AU discussion.
5 years, 5 months ago
Invion Limited is currently in a long term uptrend where the price is trading 29.5% above its 200 day moving average.
From a valuation standpoint, the stock is 93.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 17.3.
Invion Limited's total revenue sank by 32.9% to $1M since the same quarter in the previous year.
Its net income has increased by 27.8% to $-852K since the same quarter in the previous year.
Finally, its free cash flow grew by 85.0% to $-49K since the same quarter in the previous year.
Based on the above factors, Invion Limited gets an overall score of 4/5.